Monoclonal antibody effective in treating life-threatening renal disease

June 6, 2013

(Medical Xpress)—Two clinical studies have shown that the monoclonal antibody eculizumab is effective in treating patients with atypical hemolytic uremic syndrome (aHUS), a life-threatening, chronic, and progressive inflammatory disease.

The results are published this week in the New England Journal of Medicine.

One of the four sites for the clinical trial in the United States was at Emory University School of Medicine and Children's Healthcare of Atlanta, and was led by principal investigator Larry Greenbaum, MD, PhD, Marcus Professor of Pediatrics at Emory and chief of nephrology at Children's. The trial was conducted in the Pediatric Research Center affiliated with the Atlanta Clinical and Translational Science Institute (ACTSI), part of the CTSA network sponsored by the National Institutes of Health.

aHUS leads to thrombotic microangiopathy (TMA), which causes blood clots in capillaries and small blood vessels. Patients with aHUS have a lifelong risk of systemic complications of TMA, including damage to multiple organ systems.

Although aHUS was previously managed with plasma exchange or infusion (PE/PI), the underlying problems persist, and end-stage or death occurs in approximately 33 to 40 percent of patients during the first clinical episode. Within a year, up to 65 percent of patients managed with PE/PI have permanent , progress to end-stage renal disease, or die. In aHUS patients who have kidney transplants, 60 to 90 percent lose the transplants within a year.

Eculizumab binds to the human C5 complement protein and blocks production of pro-. It was previously approved for the treatment of the blood disorder paroxysmal nocturnal hemoglobinuria (PNH), and the results of these trials led to of eculizumab for the treatment of aHUS.

The two Phase 2 studies enrolled a total of 37 patients who were not responding to PE/PI or who had no platelet count decrease >25 percent for 8 weeks during PE/PI. Participants in each study were treated for 26 weeks and longer-term extensions. Effectiveness was measured by an increase in platelet counts and TMA event-free status (no platelet decrease >25 percent, PE/PI, or new dialysis). Secondary measures were renal outcomes, health-related quality of life, and safety.

The studies found that eculizumab significantly reduced complement-mediated TMA, as indicated by normalization of hematologic measures and reduction in interventions for TMA. In the first trial, the platelet count significantly increased from baseline. In the second, 80 percent of the patients had TMA event–free status.

Eculizumab also resulted in significant improvement in all secondary measurements. In one of the studies, four out of five patients receiving dialysis were able to discontinue dialysis following initiation of eculizumab. Earlier intervention was associated with significantly greater improvement in kidney function. No cumulative toxicity or serious infection-related adverse events were found.

"This study showed that eculizumab is effective in treating patients with this chronic, life-threatening disease, and we were pleased to be one of the participating sites," says Greenbaum. "This drug is a true therapeutic breakthrough for these ."

Explore further: Certain mutations affect kidney disease risk and prognosis

Related Stories

Certain mutations affect kidney disease risk and prognosis

February 21, 2013
Certain gene mutations affect individuals' risk of developing a serious kidney condition, as well as their prognosis after being diagnosed with the disease, according to a study appearing in an upcoming issue of the Journal ...

Antibodies successful in the treatment of the hemolytic-uremic syndrome from EHEC

May 31, 2011
In the online version of the New England Journal of Medicine, physicians and scientists in Heidelberg, Montreal, and Paris reported on the successful treatment of three young children who were suffering from a severe hemolytic-uremic ...

Quality of life and treatment of late-stage chronic kidney disease

September 11, 2012
Renal transplantation is best treatment option for improving quality of life in people with late-stage chronic kidney disease

Racial disparities exist in end-of-life care for US dialysis patients

April 11, 2013
At the end of life, black patients with kidney failure receiving chronic dialysis are less likely to be referred to hospice and to discontinue dialysis compared with white patients, according to a study appearing in an upcoming ...

Robotic transplant an option for obese kidney patients

May 15, 2013
Obese patients who received robotic kidney transplants had fewer wound complications than patients who received traditional "open" transplant surgery, according to surgeons at the University of Illinois Hospital & Health ...

Routine cinacalcet for end stage kidney disease not warranted

April 30, 2013
Cinacalcet, a drug commonly given to patients with end stage kidney disease to help keep phosphorus and parathyroid blood levels within a target range and has few patient level clinical benefits and several adverse effects, ...

Recommended for you

Urine test developed to test for tuberculosis

December 14, 2017
(Medical Xpress)—An international team of researchers has developed a urine test that can be used to detect tuberculosis (TB) in human patients. In their paper published in Science Translational Medicine, the group describes ...

40 years after first Ebola outbreak, survivors show signs they can stave off new infection

December 14, 2017
Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks, according to a new study ...

Lactic acid bacteria can protect against Influenza A virus, study finds

December 13, 2017
Lactic acid bacteria, commonly used as probiotics to improve digestive health, can offer protection against different subtypes of influenza A virus, resulting in reduced weight loss after virus infection and lower amounts ...

Lyme bacteria survive 28-day course of antibiotics months after infection

December 13, 2017
Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced results of two papers published in the peer-reviewed journals PLOS ONE and American Journal of Pathology, that seem to support ...

Aging impairs innate immune response to flu

December 13, 2017
Aging impairs the immune system's response to the flu virus in multiple ways, weakening resistance in older adults, according to a Yale study. The research reveals why older people are at increased risk of illness and death ...

Drug blocks Zika, other mosquito-borne viruses in cell cultures

December 12, 2017
If there was a Mafia crime family of the virus world, it might be flaviviruses.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.